Description of Research Expertise:
My research interests focus on improving outcomes in patients with lymphomas using novel agents and immune based therapies. I have served as the principal investigator on several trials including multicenter investigator initiated trial using brentuximab (immunoconjugate) in combination with chemotherapy as frontline treatment for CD30+ B cell lymphomas. I have also conducted a pilot trial using chimeric antigen receptor (CAR) T cells in patients in relapsed/refractory Hodgkin lymphoma and served as co-investigator on trials using CAR T cells in non-Hodgkin lymphomas. More recently, I have been involved in collaborative work with our translational scientists which may allow us to find new therapeutic targets for cellular therapies in Hodgkin lymphoma.
Selected Publications:
Mato AR, Roeker LE, Allan JN, Pagel JM, Brander DM, Hill BT, Cheson BD, Furman RR, Lamanna N, Tam CS, Handunnetti S, Jacobs R, Lansigan F, Bhavsar E, Barr PM, Shadman M, Skarbnik AP, Goy A, Beach DF, Svoboda J, Pu JJ, Sehgal AR, Zent CS, Tuncer HH, Schuster SJ, Pickens PV, Shah NN, Rhodes J, Ujjani CS, Nabhan C.: Outcomes of front line ibrutinib treated CLL patients excluded from landmark clinical trial Am J Hematol 93 (11): 1394-1401,2018.
Shah NN, Nagle SJ, Torigian DA, Farwell MD, Hwang WT, Frey N, Nasta SD, Landsburg D, Mato A, June CH, Schuster SJ, Porter DL, Svoboda J.: Early positron emission tomography/computed tomography as a predictor of response after CTL019 chimeric antigen receptor–T-cell therapy in B-cell non-Hodgkin lymphomas Cytotherapy 20 (12): 1415-1418,2018.
Bange E, Timlin C, Kabel C, Svoboda J, Roeker L, Mato AR.: Evidence for and Against Green Tea and Turmeric in the Management of Chronic Lymphocytic Leukemia Clin Lymphoma Myeloma Leuk 18 (10): e421-e426,2018.
Farhan A, Chong EA, Schuster SJ, Strelec L, Nasta SD, Landsburg D, Svoboda J.: Bexarotene in Patients with Peripheral T-cell Lymphomas: Results of a Retrospective Study Clin Lymphoma Myeloma Leuk 19 (2): 109-115,2019.
Cherng HJ, Sargent RL, Nasta SD, Svoboda J, Schuster SJ, Mato AR, Schrank-Hacker A, Morrissette JJD, Landsburg DJ.: Interim PET/CT Result Is Not Predictive of Survival in Patients With MYC-rearranged Non-Burkitt Aggressive B-cell Lymphoma. Clin Lymphoma Myeloma Leuk 18 (10): 673-678,2018.
Ruan J1, Martin P1, Christos P2, Cerchietti L1, Tam W3, Shah B4, Schuster SJ5, Rodriguez A1, Hyman D1, Calvo-Vidal MN1, Smith SM6, Svoboda J4, Furman RR1, Coleman M1, Leonard JP1.: Five-year follow-up of lenalidomide plus rituximab as initial treatment for mantle cell lymphoma. Blood 132 (19): 2016-2025,2018.
Svoboda J, Rheingold SR, Gill SI, Grupp SA, Lacey SF, Kulikovskaya I, Suhoski MM, Melenhorst JJ, Loudon B, Mato AR, Nasta SD, Landsburg DJ, Youngman MR, Levine BL, Porter DL, June CH, Schuster SJ.: Non-viral RNA chimeric antigen receptor modified T cells in patients with Hodgkin lymphoma. Blood 132 (10): 1022-1026,2018.
Mato AR, Thompson M, Allan JN, Brander DM, Pagel JM, Ujjani CS, Hill BT, Lamanna N, Lansigan F, Jacobs R, Shadman M, Skarbnik AP, Pu JJ, Barr PM, Sehgal AR, Cheson BD, Zent CS, Tuncer HH, Schuster SJ, Pickens PV, Shah NN, Goy A, Winter AM, Garcia C, Kennard K, Isaac K, Dorsey C, Gashonia LM, Singavi AK, Roeker LE, Zelenetz A, Williams A, Howlett C, Weissbrot H, Ali N17, Khajavian S11, Sitlinger A4, Tranchito E7, Rhodes J2, Felsenfeld J3, Bailey N, Patel B, Burns TF, Yacur M, Malhotra M, Svoboda J: Real world outcomes and management strategies for venetoclax-treated chronic lymphocytic leukemia patients in the United States. Haematologica 103 (9): 1511-1517,2018.
Bair SM, Mato A, Svoboda J.: Immunotherapy for the Treatment of Hodgkin Lymphoma: An Evolving Paradigm. Clin Lymphoma Myeloma Leuk 18 (6): 380-391,2018.
Jia Ruan, Peter Martin, Paul J Christos, Leandro Cerchietti, Bijal D Shah, Stephen J Schuster, Wayne Tam, Amelyn Rodriguez, David Hyman, Maria Nieves Calvo Vidal, Lidia Roman Gonzalez, Sonali M Smith, Jakub Svoboda, Richard R Furman, Morton Coleman, John P Leonard: Initial Treatment with Lenalidomide Plus Rituximab for Mantle Cell Lymphoma: 5-Year Follow-up and Correlative Analysis from a Multi-Center Phase II Study Blood/American Society of Hematology Annual Meeting, Atlanta, GA 130 : 154-154,2017.